✦ LIBER ✦

Phase II Study of first-line chemotherapy using CT-2103 in patients with Non-Small-Cell Lung Cancer who are > or = 70 years of age or who have PS = 2

Book ID: 117659772
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 159 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)81083-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

806 Phase 2 study of first line chemothe

806 Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX) in patients with non-small-cell lung cancer who are > 69 years of age or who have performance status (PS) = 2

✍ D. Bodkin; M. Neubauer; M.G. Bolton 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

O-140 Phase 2 study of first line chemot

O-140 Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX™) in patients with non-small-cell lung cancer who are ≥ 70 years of age or performance status (PS) = 2

✍ Bodkin, David; Neubauer, Marcus; Bolton, Mary G. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Phase 2 trial of docetaxel and gefitinib

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older

✍ George R. Simon; Martine Extermann; Alberto Chiappori; Charles C. Williams; Mube 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

## Abstract ## BACKGROUND This is a phase 2 study of chemotherapy‐naive patients, 70 years of age or older, with nonsmall‐cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progress

Phase II study of erlotinib for chemothe

Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets

✍ Dae Ho Lee; Sang-We Kim; Cheolwon Suh; Yun Hee Han; Jung-Shin Lee 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 241 KB

O-4 A randomized phase II study of docet

O-4 A randomized phase II study of docetaxel versus docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first line chemotherapy

✍ Groen, H.J.M.; Wachters, F.M.; Biesma, B.; Schramel, F.M.N.H.; Stigt, J.A.; Smit 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 188 KB

O-110 Preliminary results of a phase II

O-110 Preliminary results of a phase II study of celecoxib and weekly docetaxel in elderly (> 70 yrs) or PS2 patients with advanced non-small cell lung cancer (NSCLC)

✍ Gadgeel, Shirish M.; Shehadeh, Nasfet; Kraut, Michael J.; Wozniak, Antoinette; B 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 189 KB